Immunotherapy : Episode 12

Video

Epsiode 12 - Healthcare Reform's Impact on Immunotherapy (Part 1)

The Supreme Court’s approval of the Affordable Care Act leads the panelists into a discussion about how healthcare reform will affect the coverage of treatment modalities such as immunotherapy.

Although it remains unclear how the new system will affect cancer care, Daniel George, MD, believes that patients will benefit.

Jeffrey Weber, MD, PhD, explains that under “Obamacare” fewer patients will be uninsured. As a result, practitioners will be able to see and treat more patients.

The panelists agree that under the new system professionals will be able to treat patients with immunotherapy because patients will now have coverage to receive treatment. Before, immunotherapy was not always an option.

Additionally, Dr Weber explains that healthcare reform should not affect smaller practices any differently from larger practices. However, the panelists agree that it will be necessary under the new care system that any issues of wasteful spending be addressed, as this is currently extremely common.


Related Videos
Casey Koch, PharmD, sitting for a video interview
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Kimlin Tam Ashing
Jaime Almandoz, MD, MBA
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo